Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Rilapladib and Itraconazole Interaction
NCT02130661Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Oct 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of rilapladib in Alzheimer's disease (AD) (2 arms), sponsored by GSK. Primary endpoints: Maximum Observed Concentration at Day 14, Time of Occurrence of Cmax at Day 14 and 5 more. Planned start Oct 2017; status: withdrawn.
02
Drugs
rilapladib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02130661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130661.